Browse drugs

…median disease duration 2 years (IQR 1.5-3.5) were treated with teclistamab ( table 1). 3/4 patients suffered from interstitial lung diseas…

…fractory SSc with the plasma cell-depleting bispecific antibody teclistamab ( table 1). After six cycles of teclistamab, 1g of rituximab wa…

…arlatamab, epcoritamab, glofitamab, mosunetuzumab, talquetamab, teclistamab, and elranatamab. Eligibility criteria were abstracted for excl…

…ytotoxicity data from three TCEs (teclistamab, elranatamab, and epcoritamab). Hypothetical experiments were simulated to explore possible i…

…ds, and anti-CD38 monoclonal antibodies such as daratumumab and isatuximab. CD38 is expressed at high levels in the hematopoietic system, …